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Abstract
Ubiquitin-dependent processes control much of cellular physiology. We show that expression of a highly active, Epstein-Barr
virus-derived deubiquitylating enzyme (EBV-DUB) blocks proteasomal degradation of cytosolic and ER-derived proteins by
preemptive removal of ubiquitin from proteasome substrates, a treatment less toxic than the use of proteasome inhibitors.
Recognition of misfolded proteins in the ER lumen, their dislocation to the cytosol, and degradation are usually tightly
coupled but can be uncoupled by the EBV-DUB: a misfolded glycoprotein that originates in the ER accumulates in
association with cytosolic chaperones as a deglycosylated intermediate. Our data underscore the necessity of a DUB activity
for completion of the dislocation reaction and provide a new means of inhibition of proteasomal proteolysis with reduced
cytotoxicity.
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Introduction
Protein quality control and ubiquitin-dependent degradation
are essential for cellular homeostasis and survival [1]. The
ubiquitin-proteasome-system (UPS) is responsible for the turnover
of most cytosolic proteins. Likewise, secreted and membrane
proteins that do not fold properly or fail to associate with their
requisite partners in the ER are delivered to the cytosol and then
destroyed by the UPS [2]. To facilitate this reaction, one or several
dedicated receptors recognize misfolded ER-luminal proteins,
which are then recruited to the dislocation machinery and
rendered accessible to the cytosolic ubiquitylation apparatus. For
both cytosolic and ER-derived substrates, attachment of poly-
ubiquitin (poly-Ub) chains by an enzymatic E1-E2-E3 cascade is
the signal for proteasomal degradation [3]. Poly-Ub chains serve
as a recognition signal also for protein dislocation from the ER [4].
When an ER-derived misfolded protein gains access to the cytosol,
the attachment of a poly-Ub chain recruits the cytosolic ATPase
p97/VCP/CDC48 (Swiss-Prot ID: P55072) and its associated co-
factors Ufd1-Npl4 [5–7], believed to provide the force required for
extraction of substrate from the ER. It is not known whether these
Ub-chains are utilized as a handle to exert a mechanical force or
whether they target the dislocated protein directly to the
proteasome [5,6,8].
The 19S lid of the 26S proteasome and p97/VCP/CDC48
both occur in association with ubiquitin ligase and deubiquitylat-
ing activities [9,10]. Ubiquitylation is a dynamic process, tightly
controlled by a collection of associated ubiquitin-processing
factors, both at the level of the proteasome and at the level of
p97 [9,10]. Ubiquitylation and its reverse reaction, catalyzed by
deubiquitylating enzymes (DUBs), are crucial for p97-mediated
dislocation and for proteasome function [3,5]. Impairment of p97-
associated DUB activity can block substrate dislocation [11,12].
The removal of poly-Ub chains by DUBs associated with the
proteasomal lid precedes the threading of unfolded proteins
through a narrow pore into the proteolytic chamber of the core
20S proteasome [1,13,14]. The removal of Ub prior to
degradation also recycles this essential modifier and replenishes
the cellular pool of free Ub. It follows that DUB activity can have
distinct outcomes for proteasomal turnover of proteins: some
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DUBs facilitate degradation, whereas others may stabilize proteins
destined for degradation.
Removal of glycoproteins from the ER involves multiple distinct
enzymatic reactions: ubiquitylation, deubiquitylation, deglycosyla-
tion, and ATP-dependent dislocation [2]. How are the opposing
activities of ubiquitylation and debuiquitylation coupled in the
course of extraction from the ER and delivery to the proteasome?
The activity of DUBs is no less carefully controlled than that of the
ligases that carry out ubiquitylation. The catalytic domains of
DUBs, both cellular and viral, are flanked by often sizable
segments that likely mediate such control [12,15,16]. We reasoned
that the expression of a highly active DUB protease domain,
excised from its normal context, might preemptively remove Ub
from substrates targeted for degradation and stabilize them. We
chose the protease domain of the Epstein-Barr Virus (EBV) large
tegument protein (BPLF1, Swiss-Prot ID: P03186) for that
purpose. We use this EBV-DUB to cause an enzymatic blockade
of the UPS and show that its expression uncouples dislocation
from degradation. Our data demonstrate that protein dislocation
from the ER requires a DUB activity upstream of p97-mediated
extraction from the ER. Furthermore, a side-by-side comparison
of different experimental strategies that impede degradation of a
misfolded ER-luminal substrate enabled us to identify this
substrate’s interactors at distinct stages en route to degradation.
This allows us to propose a timeline for the discrete steps involved.
We further identify the ER-luminal machinery for disulfide
bridge formation as a putative target of eeyarestatin-I, a small-
molecule inhibitor of dislocation. The cytosolic co-chaperone
recruiter BAT3 (Swiss-Prot ID: P46379) surfaces as a specific
interactor of an ER-derived—and now cytosolic—substrate when
the UPS is blocked by the EBV-DUB. Our data suggest a
previously unanticipated function of cytosolic chaperones, namely
to cope with ER-derived misfolded proteins that arrive in the
cytosol. The consequences of EBV-DUB expression are less toxic
than those caused by pharmacological proteasome inhibitors and
might find wide application in cell biology.
Results
EBV-DUB Is a Highly Active, Viral Ubiquitin-Specific
Protease
We aimed to shift the balance of ubiquitylation towards
deubiquitylation through enforced expression of a highly active
DUB. To this end we employed the protease domain (aa1-270) of
the EBV BPLF1 gene (Figure 1A) [16]. The isolated protease
domain (EBV-DUB) hydrolyzed K48 Ub-linkages more readily
(.10-fold) than preparations of the cellular DUB YOD1 (Swiss-
Prot ID: Q5VVQ6) (Figure 1B). The EBV-DUB was an excellent
substrate for the activity-based probe HA-Ub-VME [17], but not
when the putative catalytic cysteine was substituted to alanine
(C61A) or when Ub-binding was abolished through blocking the
catalytic cleft of the EBV-DUB by an I173W mutation
(Figure 1A,C). BPFL1 is active towards both K48- and K63-linked
di-Ub, as well as NEDD8 [18], but not against linear di-Ub despite
its topological similarity to K63-linked Ub (Figure 1D) [19]. The
cellular function of BPLF1’s DUB activity remains largely
unknown [20]. Our experiments do not address the hydrolysis of
poly-Ub chains of other linkage types, including K11, or chains of
mixed topologies, all of which could contribute to proteasomal
targeting to different degrees [21]. K63 linkages have been linked
primarily to endocytosis and other non-proteasomal events [22]
but could contribute to protein homeostasis as well [23,24]. As a
control for all subsequent experiments, we employed the I173W
mutant unable to bind and hydrolyze Ub-chains (Figure 1A,C,E).
Expression of a FLAG tagged variant of the wild-type EBV-
DUB in 293T cells resulted in a substantial downward shift of
polyubiquitylation in HA-ubiquitin expressing cells (Figure 2A). In
contrast, the expression of a cellular, less active DUB (YOD1 WT)
failed to do so. Consistent with previous observations, the
catalytically inactive mutant (YOD1 C160S) caused accumulation
of polyubiquitylated proteins, presumably due to stalled disloca-
tion [11]. The efficiency with which the viral DUB eliminated
polyubiquitylated conjugates in living cells is even more apparent
when the activity of the proteasome is blocked by prior exposure of
cells to ZL3VS: polyubiquitylated proteins now accumulated in
control cells but were largely absent from EBV-DUB WT cells
when examined at similar sensitivity of detection (Figure 2A). To
corroborate our findings, we repeated our experiments in the
absence of co-transfected HA-Ub. Immunoblots using antibodies
directed against ubiquitin or specific for Lys48-linked ubiquitin
revealed diminished polyubiquitylation in EBV-DUB WT cells,
but not in control cells (Figure S1).
A strong reduction in polyubiquitylation should affect protein
turnover globally. Therefore we analyzed the effect of EBV-DUB
expression on steady-state levels of two short-lived, cytosolic GFP
variants: the ubiquitin-fusion degradation (UFD) substrate Ub-
G76V-GFP and the N-end rule substrate Ub-R-GFP (Figure 2B)
[25]. Both proteins are unstable and their detection improves upon
inhibition of the UPS. Ub-R-GFP is processed by cellular
ubiquitin hydrolases, which results in exposure of arginine as the
N-terminal destabilizing residue [26]. Ub-G76V-GFP cannot be
processed by cellular hydrolases, but the fusion with ubiquitin itself
serves as a degradation signal [27].
Co-expression of Ub-G76V-GFP and EBV-DUB WT gave rise
to a population with high GFP fluorescence, best illustrated by the
5.3-fold higher median fluorescence intensity of GFP-positive cells
(MFI) as compared to control cells and the 1.8-fold increased MFI
Author Summary
Constant turnover of proteins is part of normal cellular
physiology. Newly synthesized proteins that fail to fold are
recognized by dedicated receptors and tagged for
immediate degradation. The tag usually consists of a chain
of a small protein, ubiquitin, and is recognized by the
proteasome. We introduce a new tool to interfere with
proteasomal degradation: a ubiquitin-specific protease
domain (EBV-DUB) derived from Epstein-Barr Virus. This
EBV-DUB, when expressed in mammalian cells, preemp-
tively removes ubiquitin chains (deubiquitylation) and so
frustrates substrate recognition and engagement by the
proteasome. The natural history of misfolded, secretory
proteins is poorly understood because of the strict
coupling of recognition, tagging for degradation, and
proteolysis. The EBV-DUB uncouples these processes and
stabilizes short-lived intermediates, an activity that helped
us to address the question of how such misfolded proteins
are extracted from the relevant cellular compartments. Our
data are consistent with the idea that unfolded substrates
targeted for degradation are threaded through a narrow
pore of the chaperone protein known as p97. In order to
pass through the pore, the protein must first have any
already attached ubiquitin chains removed; a second cycle
of ubiquitylation is then required to allow engagement of
the proteasome. Entry of substrate into the proteolytic
chamber again requires removal of ubiquitin. We thus
propose two rounds of ubiquitin attachment and removal
in the course of the extraction and degradation of
misfolded proteins.
A Viral DUB Blocks Ubiquitin-Dependent Proteolysis
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compared to cells treated with the proteasome inhibitor ZL3VS
(Figure 2B). Similarly, Ub-R-GFP and EBV-DUB co-expressing
cells exhibited a 4.4-fold higher MFI compared to control cells and
a 1.6-fold higher MFI compared to ZL3VS-treated cells, apparent
also when titrating ZL3VS (Figure S2). As expected, the relative
fraction of GFP-positive cells increased when protein degradation
was impaired (Figure 2B). ZL3VS is an efficient inhibitor of the
chymotryptic and the peptidyl-glutamyl peptide hydrolyzing
activities of the proteasome and impairs its tryptic activity by
,50% [25,28]. Taking this into account, our flow cytometric data
on two well-established, short-lived proteins suggest a near
complete blockade of the UPS [25,29]. Both the N-end rule and
UFD pathway are affected, likely at an ubiquitinyl-dependent step
in commitment of the substrate to the proteasome.
Ubiquitylation and protein turnover are central to many cellular
processes. Overexpression of a highly active DUB or proteasomal
inhibition by small molecules might affect the physiology of a cell
in many ways. Pharmacological inhibition of the proteasome
Figure 1. EBV-DUB is a highly active enzyme in vitro. (A) The left panel shows a ribbon representation of the M48 protease domain from the
mouse cytomegalovirus (MCMV) (PDB code: 2J7Q) [16]. Depicted in cyan is the extended C-terminus of Ub in the M48 active-side cleft pointing
towards the catalytic cysteine (C23), shown in yellow. The right panel shows a structural model of EBV-DUB I173W, with the catalytic cysteine (C61)
depicted in yellow and the tryptophane 173 point mutation, blocking the catalytic cleft, shown in red. (B) YOD1 WT, YOD1 C160S, and EBV-DUB WT
(1 mg) were incubated with 0.5 mg of K48-linked diUb for 3 h at 37uC. The amount and concentration of the EBV-DUB WT was titrated as indicated. The
reaction was stopped by boiling in sample buffer, subjected to SDS-PAGE, and immunoblotted with anti-Ub antibody. (C) Purified YOD1 and EBV-DUB
(WT and indicated mutants) were incubated at a molar ratio of 1:1 with HA-Ub-VME, an activity-based probe [17], and subjected to SDS-PAGE. When
indicated, NEM was included in the reaction mixture. HA-Ub-VME adduct formation was visualized by immunoblotting with anti-HA antibodies.
Purified EBV-DUB is proteolytically processed and runs as a double band, however both forms promote adduct formation with the HA-Ub-VME probe.
(D) K48-linked, K63-linked, or linear diUb (0.5 mg) was incubated for 3 h at 37uC in a total volume of 10 ml with EBV-DUB WT (1 mg). The reaction
mixture was subjected to SDS-PAGE and silverstained. (E) EBV-DUB WT, the C61A mutant, and the I173W mutant of the EBV-DUB were incubated with
K48-linked diUb (0.5 mg) for 3 h at 37uC. The reaction mixture was subjected to SDS-PAGE and immunoblotted with anti-Ub antibody.
doi:10.1371/journal.pbio.1000605.g001
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impairs de novo protein synthesis [30,31]. In our hands, treatment
of cells with ZL3VS for 40 min resulted in ,40% reduced
incorporation of radioactivity in a 10 min pulse labeling
experiment when compared to control and EBV-DUB expressing
cells (Figure 2C). Thus, de novo protein synthesis was impaired
upon pharmacological inhibition but remained unperturbed in
EBV-DUB cells. Prolonged treatment (20 h) of cells with
proteasome inhibitors caused growth arrest and changes in cell
morphology, consistent with the known ability of proteasome
inhibitors to induce apoptosis and cell cycle arrest [25,32]. EBV-
DUB cells appeared normal at times of cultivation where ZL3VS
treated cells were morphologically aberrant (.26 h) (Figure 2D),
but after much longer cultivation they, too, succumbed, presum-
ably because the continued operation of the UPS is essential for
cell survival.
Expression of EBV-DUB Blocks Protein Turnover
Does expression of the viral DUB affect protein degradation
directly? To allow a direct comparison of an ER-derived and
cytosolic substrate, we employed RI332, a C-terminally truncated
form of ribophorin-I that is commonly used as a model to study
dislocation and degradation of ER-luminal proteins [11,33,34].
When devoid of its N-terminal signal sequence (DSS-RI332) the
protein fails to enter the ER, cannot be glycosylated, and remains
cytosolic, but is otherwise identical to RI332 (see schematic
representation in Figure 3E). The cytosolic UPS substrate DSS-
RI332 is turned over in both control and EBV-DUB I173W cells
(t1/2 = 20 min), but its degradation was blocked by expression of
EBV-DUB WT (Figure 3A). This confirms our flow cytometric
data on Ub-R-GFP and Ub-G76V-GFP (Figure 2B) and
demonstrates an efficient blockade of the UPS imposed by EBV-
DUB WT. An arrest of the UPS should also affect the degradation
of ER-derived proteins. When equipped with its natural signal
sequence, RI332 is translocated into the ER and glycosylated
but rapidly destroyed in control and EBV-DUB I173W cells
(t1/2 = 44 min) (Figure 3B) [33].
The banding pattern observed in these experiments requires
explanation. The lower band at the 0 min chase time point
corresponds to ER-luminal, non-glycosylated RI332 (RI332 no
CHO) with its signal sequence removed, while the upper band is
the glycosylated form of RI332 (RI332 +CHO) [11]. Removal of
the N-linked glycan by cytosolic N-glycanase converts asparagine
at the site of glycan attachment to aspartate (N275D) [35]. As a
consequence, deglycosylated RI332 (RI332-CHO) shows altered
electrophoretic mobility. This form was readily apparent in EBV-
DUB WT cells after a 90 min chase and beyond (Figures 3B, S3)
and can arise only as a consequence of glycan removal from
previously glycosylated RI332. Such deglycosylated intermediates
are normally rapidly degraded by the proteasome and therefore
escape detection, unless the activity of the proteasome is
compromised [33].
Co-expression of the EBV-DUB stabilized RI332, but did not do
so completely (Figure 3B). Since dislocation and proteolysis are at
least to some extent coupled processes [33,36], we reasoned that
some Ub-chains present on ER-derived dislocation substrates
might not be accessible to the EBV-DUB. We therefore targeted
the viral DUB domain to p97, the ‘‘motor of dislocation,’’ by
equipping it with the UBX domain of YOD1 to copy the strategy
employed by this cellular DUB. This chimeric protein (UBX-EBV
WT) associated with p97 (Figure S4) and blocked degradation of
the ER-derived RI332 substrate completely (Figure 3B, UBX-
fusion).
The degradation of two unrelated membrane proteins—the
polytopic transmembrane protein insig-1 and the glycosylated a-
chain of the T-cell receptor (TCRa) with one transmembrane
helix (Figure 3E)—were likewise affected. Expression of UBX-
EBV WT halted the turnover of myc-tagged insig-1, an ER-
localized transmembrane protein that regulates cholesterol
synthesis (Figure 3C) [8]. Of note, insig-1-myc is not a
glycoprotein but has two alternative start codons yielding two
translation products with distinct electrophoretic mobilities [37].
Also the degradation TCRa, an unstable protein when expressed
in the absence of other T-cell receptor subunits, was blocked upon
co-expression of UBX-EBV WT (Figure 3D). In summary, the
EBV-DUB arrests turnover of cytosolic and ER-derived proteins.
In all cases, targeting of the viral DUB to p97 improved the
stabilization of ER-derived substrates, but its activity towards
cytosolic substrates of the UPS persisted (Figures 3, S5).
Uncoupling Protein Dislocation and Degradation
The occurrence of the deglycosylated RI332 intermediate that
accumulated in UBX-EBV WT and in EBV WT cells (RI332 –
CHO; Figure 3B) was informative. Since N-glycanase is confined
to the cytosol [35,38], this observation immediately suggested that
the single N-linked glycan of RI332 gained cytosolic exposure and
therefore that dislocation must have occurred, entirely or in part.
However, when turnover of RI332 was inhibited by expression of
YOD1 C160S, the deglycosylated form RI332 was not observed,
even after long chase periods (Figure 4A), indicating its
confinement to the ER. The appearance of deglycosylated
intermediates was not specific for the ER-luminal RI332 but was
readily observable as well for TCRa when co-expressed with
UBX-EBV WT (Figure 3D). For reasons that remain to be
determined, we consistently observe greater recovery of label for
TCRa at later chase points. It is possible that detergent extraction
of newly synthesized TCRa is somehow less efficient than material
that has left the site of membrane insertion. We do not observe a
similar discrepancy for the other substrates analyzed, insig-1 and
RI332.
We confirmed cytosolic accessibility of the deglycosylated RI332
intermediate by a proteinase K protection experiment in
mechanically disrupted cells (Figure 4B). In the absence of
detergent, only deglycosylated RI332 (RI332 – CHO) was
accessible to protease. The glycosylated, ER-luminal form
(RI332 + CHO) was not affected by the protease under identical
conditions and serves as an internal control for membrane
integrity (Figure 4B). Proteinase K sensitivity of deglycosylated
RI332 implied that a substantial portion of RI332, if not RI332 in its
entirety, was exposed to the cytosol in UBX-EBV WT expressing
cells. To further corroborate this result, we performed a
Figure 2. A viral DUB switches the cellular ubiquitylation balance towards deubiquitinylation and blocks proteasomal degradation.
(A) Lysates of 293T cells transfected as indicated and immunoblotted with anti-HA, anti-p97, and anti-Flag antibodies. Where indicated, cells were
treated with for 10 h with 10 mM ZL3VS. (B) Flow-cytometric analysis of 293T cells treated and co-transfected with as indicated. The gate was set to
identify GFP-positive, live cells. Quantified is the median fluorescence intensity (MFI) of GFP-positive cells. (C) Pulse-labeling experiment and
quantification of de novo protein synthesis. Where indicated, cells were starved and radiolabeled in the presence of 50 mM ZL3VS. Radioactivity
incorporated by control cells was normalized to 100%. The error bars depict the standard deviation (n=4). (D) Morphology changes of 293T cells 26 h
after transfection and after treatment for 20 h with 10 mM of indicated proteasome inhibitors.
doi:10.1371/journal.pbio.1000605.g002
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fractionation experiment in which we made use of the pore-
forming toxin Perfringlolysin O (PFO) [39]. UBX-EBV WT cells
were pulse labeled and the radiolabeled, deglycosylated interme-
diate of RI332 was enriched during a 90 min chase period
(Figure 4C). After selective permeabilization of the plasmamem-
brane by PFO, the cytosolic fraction was separated from cellular
remnants by centrifugation, in the presence or absence of added
high salt to ensure release of peripherally membrane-associated
materials. Only for UBX-EBV WT cells did we see release of the
deglycosylated RI332 (RI332 – CHO) into the supernatant fraction
(S), even more pronounced in the presence of high salt (S’).
However, glycosylated RI332 (RI332 + CHO) was retained in the
pellet fraction under all conditions, consistent with an ER-luminal
localization. PFO permeabilization did not damage intracellular
Figure 3. Expression of a viral DUB blocks degradation of cytosolic, ER-luminal, and ER-membrane proteins. (A–D) Pulse-chase analysis
with unstable model substrates: (A) cytosolically localized DSS-RI332, (B) the ER-luminal glycoprotein RI332, (C) Insig-1, a multi-spanning membrane
protein of the ER, and (D) TCRa, a glycosylated protein with one transmembrane helix. (E) Unstable model proteins used throughout this study are
shown schematically. After indicated chase times, the model substrates were immunoprecipitated, subjected to SDS-PAGE, and quantified (right
panels). The influence of targeting the EBV-DUB to p97 through installation of an UBX-domain (red symbols) versus non-targeted EBV-DUB (black
symbols) is tested by direct comparison of model substrate stabilization. The error bars correspond to the standard deviation (n= 3). See Figure S3 for
UBX-mediated targeting to p97.
doi:10.1371/journal.pbio.1000605.g003
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Figure 4. ER-dislocation and protein degradation are uncoupled by p97-targeted EBV-DUB. (A) 293T cells were co-transfected with RI332
and the indicated constructs and subjected to pulse chase analysis. (B) 293T cells were co-transfected with the indicated constructs, disrupted
mechanically, and treated with proteinase K and/or NP40 as indicated. The UBX-EBV-DUB served as control for a cytosolic protein. (C) 293T cells were
co-transfected as indicated and pulse labeled. After 0 min or 90 min of chase, the cells were subjected to a subcellular fractionation experiment, after
A Viral DUB Blocks Ubiquitin-Dependent Proteolysis
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compartments, as verified by complete retention of the ER-
resident chaperone PDI (Figure 4C) in the particulate fraction.
We conclude that the deglycosylated form of RI332 was indeed
dislocated from the ER and arrived in the cytosol. Combined, our
observations show that expression of UBX-EBV WT uncouples
dislocation and degradation of RI332. We wondered if the
deglycosylated intermediate of RI332 once cytosolic would remain
associated with the ER or whether it might travel to a different
location. Immunofluorescence microscopy showed that RI332
localized to the ER in UBX-EBV WT expressing cells, with no
evidence of obvious aggregation (Figure 4D). In light of the
fractionation data, this suggests that upon dislocation, a sizable
fraction of deglycosylated RI332 remains loosely associated with
the cytosolic face of the ER-membrane.
A DUB-Catalyzed Reaction Is Essential for Protein
Dislocation
We blocked dislocation from the ER by the expression of YOD1
C160S, which causes stabilization of ER resident, glycosylated
RI332 [11].We previously proposed that p97-mediated dislocation is
stalled under these conditions, because Ub removal is required to
allow threading of the dislocation substrate through p97’s central
pore [11]. If this interpretation is correct, then it should be possible
to reverse this block by expression of a DUB capable of attacking the
hypothetical stalled intermediate and to overcome the YOD1
C160S-imposed block. Indeed, co-expression of comparable levels
of UBX-EBV WT and YOD1 C160S (Figure 4E) resulted in the
accumulation of the deglycosylated intermediate of RI332 indicative
of dislocation (Figure 4F). Co-expression of the inactive mutant
UBX-EBV I173W failed to do so, thus excluding simple
competition of the UBX-fusion protein with other p97-interactors
as the explanation. Consistently, even the non-targeted EBV-DUB
without fused UBX-domain could relieve the blockade of
dislocation imposed by YOD1 C160S (Figure 4F).
We conclude that a DUB-catalyzed reaction is essential for
protein dislocation from the ER. Because ubiquitylation by HRD1-
SEL1L is required for the initial engagement of the cytosolic
dislocation apparatus [2,34,40], premature removal of ubiquitin
might also inhibit the earliest steps in this pathway, if EBV-DUB has
access to these ubiquitylated intermediates. The rate of dislocation
as determined by the disappearance of glycosylated RI332
(Figure 3B; RI332 + CHO) was not affected compared to control
cells in EBV-WT expressing cells, but was lower in cells expressing
the p97-targeted variant (Figure 3B, UBX-fusion; Figure S3). Thus,
the non-targeted form of the EBV-DUB interfered exclusively with
the degradation of already dislocated RI332, while the ER-targeted
variant stabilized RI332 at the initiation of dislocation and through
prevention of delivery to the proteasome by preemptive removal of
poly-Ub chains from the substrate. Nevertheless, both variants, p97-
targeted or not, caused accumulation of deglycosylated, dislocated
RI332 in the cytosol.
Staging a Misfolded ER-Derived Glycoprotein on Its Path
to Destruction
What keeps the breakdown intermediate(s) of RI332 from
aggregation? To address this question and to gain a more global
perspective on the natural history of a misfolded protein, we staged
the different steps in degradation through identification of proteins
that interact with RI332 and its various dislocation intermediates.
Through interference with dislocation and degradation by
different means, we generated discrete intermediates in the
breakdown pathway of RI332 as explained in the preceding
sections. Using affinity tagged RI332 as a bait, we retrieved
interacting proteins from UBX-EBV WT, YOD1 C160S, or p97
QQ-expressing (an ATPase-deficient form of p97) cells [6], and
from cells exposed to the proteasome inhibitor ZL3VS or
eeyarestatin I, an inhibitor of dislocation and possibly membrane
insertion [29,41,42]. As controls, we performed immunoprecipi-
tations from cells that either did not express RI332 or that co-
expressed RI332 with YOD1 DZnf C160S, YOD1 WT, or UBX-
EBV I173W, none of which significantly perturb the dislocation/
degradation process [11]. We performed a total of nine
independent large-scale immunopurifications and analyzed each
by LC/MS/MS. We identified 836 candidate interactors and
enumerated the number of peptides that originated from each one
of them. We sought to identify interactions enriched upon
inhibition of dislocation/degradation to gain insight into their
spatial and temporal occurrence. We therefore normalized our
dataset as follows. Each candidate protein was represented by
multiple peptide fragments in different experimental conditions,
and the maximum number of peptides (MNOP) for a given
candidate was based on the condition that yielded the highest
peptide count. All interactions between RI332 and its candidate
interactors (retrieved from independent immunoprecipitation
experiments) were expressed as a percentage of the MNOP. Such
a normalized interaction matrix should facilitate the identification
of groups of proteins that responded similarly if certain discrete
steps of the dislocation/degradation pathways are perturbed.
After application of a stringent set of rules (inclusion
requirement based on a threshold number of peptides and absence
from normal serum controls; see Text S1 for details) a total of 33
candidate interactors remained (Table S1). The candidates were
arranged in three groups via k-means clustering and are depicted
in a heat map (Figure 5). The heat map is a graphical
representation of the normalized interaction matrix and visualizes
the conditions under which a particular interactor co-precipitated
with RI332.
Group 1 comprised those interactors of RI332 that were
specifically retrieved from eeyarestatin-I treated cells (Figure 5).
Consistent with an ER-luminal accumulation of RI332, we observe
the ER-luminal disulfide shuffling and/or PDI-domain containing
proteins (ERdj5, ERp72, ERp57, ERp5, PDI, and Calreticulin) in
association with RI332 (see Table S1 for Swiss-Prot IDs of
candidate interactors) [42,43].
When a protein is terminally misfolded, a family of substrate
recognition molecules targets the substrate to the dislocation
machinery. A snapshot of this type of intermediate was provided
by co-expression of YOD1 C160S or mutant p97 (QQ).
Specifically enriched interaction partners of RI332 under these
conditions clustered in group 2 and include glycan-binding and
modifying proteins (OS9, UGGT2), general ER-luminal substrate
recruiting factors and chaperones (SEL1L, Endoplasmin/GRP94,
selective permeabilization of the plasma membrane with Perfringolysin O. RI332 and PDI were retrieved after fractionation via immunoprecipitation.
When shown (S’/P’), the fractionation was performed in the presence of high salt (0.5 M). (D) Immunofluorescence of HeLa cells co-transfected with
RI332 and the indicated constructs. Endogenous PDI (red) served as an ER-marker and RI332 (green) was detected via the HA-epitope tag. Scale bar =
10 mm. (E) 293T cells were co-transfected with indicated YOD1, EBV-DUB, and RI332 constructs. Expression levels of YOD1 and the EBV-DUB were
determined from SDS-lysates after immunoblotting against the N-terminal Flag-epitope. (F) A pulse chase experiment was performed with 293T
transfected as in Figure 4E. The block in dislocation induced by YOD1 C160S can be rescued by co-expression of UBX-EBV WT and EBV-WT.
doi:10.1371/journal.pbio.1000605.g004
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DNAJC3/P58IPK), p97, and the cytosolic UBR5, implicated in
ubiquitylation according to the N-end rule [6,44–46]. Our
unbiased proteomic approach supports our earlier proposal that
YOD1 C160S blocks the dislocation reaction itself [11]. RI332 is
recognized as misassembled by OS9, SEL1L, and GRP94,
associates with p97, but cannot be extracted in YOD1 C160S
and p97 QQ cells [11,34,40,45]. Interactors that clustered in
group 2 comprised both ER-luminal and cytosolic components of
the ER-quality control machinery and UPR signaling.
After successful dislocation, misfolded proteins are targeted to
the cytosolic proteasome. Group 3 comprised those proteins that
were co-immunoprecipitated with RI332 from UBX-EBV WT or
ZL3VS treated cells. Our mass spectrometry data suggested that
the deglycosylated intermediate of RI332 associates with cytosolic
chaperones, namely the co-chaperone recruiter BAT3 and the
TRiC complex/CCT. The TRiC complex is important for
transient stabilization of nascent polypeptide chains prior to their
translocation into the ER [47,48], and BAT3 was recently
implicated in integration of tail-anchored proteins into the ER
membrane [49]. Not surprisingly, we can demonstrate an
interaction of RI332 with the proteasome when its activity was
blocked by the action of ZL3VS. The identified cytosolic
interactors of RI332 fully support our biochemical characterization
and suggest that dislocation and degradation are uncoupled in
UBX-EBV WT expressing cells.
A Cytosolic Chaperone Associates with an ER-Derived
Dislocated Protein
As corroboration of the mass spectrometry experiments, we
verified interactors of RI332 (Figure 6A) by different means.
After immunoprecipitation of RI332 from cells transfected/
treated as in the large-scale pulldown experiments, we
confirmed an interaction of RI332 with p97 when the ATPase
activity of p97 was blocked by mutation (p97 QQ). We likewise
Figure 5. The natural history of an unstable, ER-luminal glycoprotein. RI332 was immunoprecipitated from cells transfected with indicated
constructs or treated with eeyarestatin-I or ZL3VS (10 mM each). As control, one batch of cells (empty vector) was not transfected with RI332.
Co-immunoprecipitated interactors of RI332 were identified by LC/MS/MS. The maximum number of peptides (MNOP) associated with RI332 for a given
condition was set to 100% and peptides recovered from the other experimental conditions expressed as percentage of the maximum for each
candidate accordingly. After selection using a strict set of rules (see Materials and Methods), the candidates were grouped via K-means clustering. See
also the list of candidate interactors in Table S1. The color-coding represents a quantitative measure for the interaction from bright red (maximal
interaction) to dark green (minimal/no interaction).
doi:10.1371/journal.pbio.1000605.g005
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confirmed the association of SEL1L and OS9 with RI332 when
co-expression of either YOD1 C160S or p97 QQ blocked its
dislocation from the ER. We established the association of RI332
with BAT3, which required the co-expression of UBX-EBV
WT. These data hint at the existence of a chaperone-mediated
buffer to sequester dislocated proteins from the canonical de-
gradation pathway.
The mass spectrometry experiment predicted a strikingly
enriched association of PDI/PDIA1 with RI332, when cells were
treated with eeyarestatin-I. Indeed, we could verify an interaction
of these proteins when co-expressed with either YOD1 C160S or
p97 QQ or when cells were treated with eeyarestatin-I (Figure 6B).
More surprisingly, eeyarestatin-I induced the formation of SDS-
and b-mercaptoethanol-resistant adducts of PDI. The enrichment
of these adducts relative to monomeric PDI in immunoprecipitates
of RI332 was indicative for adduct formation between RI332 and
PDI upon eeyarestatin-I treatment. Similar observations were also
made for PDIA3/ERp57 (unpublished data).
Discussion
To explore the contributions of ubiquitin addition and removal
in protein extraction from the ER, we developed an enzyme-based
method to disrupt ubiquitin-dependent protein degradation. We
used a biochemical approach to analyze its effect on protein
turnover and dislocation from the ER.
A Novel Tool to Block Ubiquitin-Dependent Proteasomal
Degradation
The expression of a highly active viral DUB markedly shifts the
cellular balance towards deubiquitylation (Figures 2A, S1). Similar
to pharmacological inhibition of the proteasome, accelerated or
premature Ub removal from substrates should affect their
ubiquitin-dependent degradation. Indeed, overexpression of the
EBV-DUB blocks the degradation of several model substrates, but
without the immediate cytotoxic effects that are commonly
observed upon treatment of cells with pharmacological protea-
some inhibitors (Figure 2C,D). In view of Ub’s role in cell cycle
control, through K11-linked Ub-chain assembly by the ubiquitin
ligase APC/C [50], the ultimate demise of cells with an arrested
UPS is of course hardly surprising. The greater cytotoxicity of
pharmacological inhibition could perhaps be related to ubiquitin-
independent functions of the proteasome or reflect the critical
importance of free Ub in the cell [3,51]. Interference with the UPS
by blocking proteolysis with small molecules or by enzymatic
interference with proteasomal targeting are two fundamentally
different approaches. Small molecule proteasome inhibitors cause
an accumulation of polyubiquitylated proteins and deplete cells of
free Ub [52]. Cell viability critically depends on a pool of free Ub
and its depletion kills cells [51]. Shifting the cellular balance
towards deubiquitylation, as achieved by the EBV-DUB, does not
result in accumulation of polyubiquitylated proteins (Figure 2A)
and represents a novel means of inhibiting the UPS. Unlike the
EBV-DUB, pharmacological inhibition of the proteasome reduces
de novo protein synthesis even after relatively short times of
exposure (Figure 2C) [30,31]. Translation, protein folding,
secretion, and dislocation are interdependent processes and the
ability to block proteasomal protein degradation without imme-
diately affecting translation provides an additional benefit.
Deubiquitylation Is Essential for Protein Dislocation from
the ER
We showed previously that YOD1 C160S causes complete
retention of RI332 in the ER, a substrate otherwise extracted and
targeted for degradation (Figure 7A,B) [11]. This retention can be
reversed at least in part by expression of the p97-targeted EBV-
DUB (Figures 4F, 7C). Combined, these results demonstrate a
need for removal of Ub to achieve dislocation. Ramping down the
p97-associated DUB activity blocks dislocation but can be rescued
by an active DUB. This immediately suggests that DUBs can have
opposing functions for the degradation of ER-derived proteins.
Figure 6. BAT3 interacts with the cytosolic dislocation
intermediate of RI332 and eeyarstatin-I induces adducts of
PDI. (A, B) 293T cells transiently transfected as indicated were
homogenized in NP40 lysis buffer and subjected to immunoprecipitation
with anti-HA antibodies. As control, one batch of cells was not transfected
with RI332. Co-precipitated interactors were identified by immunoblotting
using the antibodies anti-BAT3, anti-p97, anti-SEL1L, anti-OS9 (left panels),
and anti-PDI (right panel). To control for equal loading, lysates were
subjected to immunoblotting using (A) anti-BAT3 and (B) anti-PDI
antibodies. See also the structural formula of eeyarestatin-I in Figure S6.
doi:10.1371/journal.pbio.1000605.g006
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Some DUBs might impair dislocation by reversing ubiquitylation;
others might facilitate dislocation and subsequent degradation.
Indeed, TCRa-GFP is stabilized by knockdown of USP13 but
destabilized by knockdown of Ataxin-3 [12]. Moreover, the
observed uncoupling of dislocation and degradation by the
EBV-DUB suggests that a persistently ubiquitylated state is not
essential for the physical extraction of substrate from the ER.
Misfolded proteins are escorted to the proteasome by ubiquitin
binding proteins [53,54]. It is therefore no surprise that the
removal of Ub-chains by the EBV-DUB abrogates proteasomal
turnover of these proteins. By analogy, p97-mediated extraction
would be arrested by the EBV-DUB to a similar extent if persistent
substrate modification with Ub-chains were required to exert a
mechanical force for such extraction. Indeed, protein dislocation is
slowed down, but clearly the reaction continues in cells that
express EBV-DUB (Figures 4A, S3). Together with the evident
requirement of a DUB-catalyzed reaction upstream of p97
(Figure 4E), these findings suggest that Ub-chains are not required
to exert a mechanical force on the dislocation substrate [7] but
may instead be required only as recognition signal [5].
Our data are consistent with the following model (Figure 7A).
Dislocation substrates are targeted to a dislocon that connects with
an Ub ligase activity, as exemplified by the HRD1-SEL1L
complex [2,34,45]. Consistent with its requirement for dislocation,
substrate ubiquitylation recruits p97 and the Ub-recognizing co-
factors Ufd1 and Npl4 to initiate dislocation [6,7,11,12,55]. Once
the dislocation machinery is recruited, one or several p97-
associated DUBs remove the initial Ub tag to enable ATP-
dependent threading through the central pore of p97 [7,11,12,55].
Unless p97 is coupled directly to the proteasome, for which there is
no firm experimental support at present [56], a second round of
ubiquitylation would be required to target the unfolded protein to
the proteasome, again necessitating removal of the Ub-chain prior
to its insertion into the proteolytic chamber [14]. There is of
course also a structural resemblance between the 6-fold symmet-
rical p97 complex, present in association with Ub-recognizing and
-processing factors, and the similarly equipped proteasomal cap
complex [53].
The first round of ubiquitylation would be responsible for the
engagement and proper assembly of the p97-Ufd1-Npl4 disloca-
tion complex and may involve K11-linked ubiquitin chains [21,57].
The second round would then target the dislocated, now cytosolic
protein to the proteasome like any other p97-dependent, cytosolic
substrate of the UPS [12,29,57]. Ubiquitylation-dependent events
Figure 7. A misfolded glycoprotein on its path to destruction. (A) Model of two consecutive ubiquitylation cycles that initiate dislocation and
target the substrate to the proteasome, respectively. (B) Expression of catalytically inactive YOD1 C160S impairs deubiquitylation upstream of the p97
AAA ATPase. This jams the central pore of p97 and processive threading of the dislocation substrate is arrested. In consequence, misfolded,
glycosylated proteins accumulate in the ER-lumen and as partially dislocated intermediates at the site of dislocation. (C) Expression of the highly
active EBV-DUB deubiquitylates misfolded proteins upstream of p97 and thus facilitates processive dislocation mediated by p97. Lack of proper
proteasome commitment results in accumulation of a deglycosylated, cytosolic intermediate of the misfolded protein.
doi:10.1371/journal.pbio.1000605.g007
A Viral DUB Blocks Ubiquitin-Dependent Proteolysis
PLoS Biology | www.plosbiology.org 11 March 2011 | Volume 8 | Issue 3 | e1000605
occur both upstream and downstream of p97 [53,54]. Two
consecutive rounds of ubiquitylation are conceptually similar to
the use of multiple independent ubiquitylation sites on many
standard proteasomal substrates: modification of more than a
single site on a given substrate requires sequential engagement by
a given ligase, or the involvement of more than one ligase.
The p97-targeted EBV-DUB interferes with degradation of ER-
derived substrates at two distinct steps (Figure 7C). First, it
interferes with proper initiation of dislocation by premature
removal of ubiquitin. Second, it blocks substrate degradation by
removal of the poly-Ub chains that would otherwise have
mediated delivery of the misfolded protein to the proteasome. In
the absence of a fused UBX-domain, the EBV-DUB affects to a
lesser extent the initial stages of dislocation but still strongly
inhibits proteasomal proteolysis of cytosolic substrates and ER-
derived substrates (Figures 2B, 3A,B). The EBV-DUB can even
facilitate the dislocation reaction when dislocation is otherwise
stalled by expression of YOD1 C160S (Figures 4F, 7B).
Our data establish the necessity of a DUB-catalyzed reaction
upstream of p97-mediated protein extraction from the ER. These
observations are most consistent with a model of two consecutive
rounds of ubiquitylation and deubiquitylation.
The Natural History of an ER-Luminal Glycoprotein
Dislocation Substrate
Using different tools to block protein dislocation and degrada-
tion, we identified interacting partners of a misfolded, ER-derived
glycoprotein at different stations on its road to destruction.
Starting in the ER, eeyarestatin-I was first identified as an inhibitor
of dislocation [42]. However, there is no consensus on the identity
of its molecular targets or its exact mode of action [29,41,58].
Eeyarestatin-I contains two halogenated benzene rings (Figure S6).
Bromobenzene, a hepatotoxic compound, is metabolized to
reactive metabolites (e.g. bromobenzene-3,4-oxide) and forms
covalent adducts with cellular proteins, including PDIA1, PDIA6,
and PDIA3 [59,60]. Also other halogenated aromatic derivatives
covalently modify proteins in a reaction mechanism similar to that
involving bromobenzene [61]. If the two halogenated benzene
rings of eeyarestatin-I would react similarly, formation of
covalently cross-linked adducts of PDI might ensue, consistent
with our observations that eeyarestatin-I induces SDS-resistant
adducts of PDI (Figure 6B). We therefore suggest the possibility
that the two halogenated benzene rings of eeyarestatin-I might
promote crosslinking of proteins in the ER lumen and that its
targets include the machinery for disulfide shuffling. If the
machinery for disulfide shuffling in the ER is indeed a molecular
target of eeyarestatin-I, then both import into and export from the
ER are likely to be affected, explaining the seemingly divergent
observations reported for eeyarestatin-I’s mechanism of action
[29,41,42].
By staging the process of dislocation and degradation we
identified several novel and intriguing candidate interactors for the
RI332 dislocation substrate, including proteins important in the
maturation of extracellular matrix components (PLOD1, CHPF2,
EXT2). Whether the machineries for heparan sulfate synthesis,
chondroitin sulfate synthesis, and collagen polymerization merely
undergo rapid turnover and are processed via p97 or whether they
are otherwise involved in the dislocation reaction remains to be
established.
We validated BAT3 as a cytosolic interactor of the deglycosy-
lated intermediate of RI332. This result implies not only that RI332
is dislocated from the ER but also that it remains associated with
chaperones, possibly to prevent aggregation. This type of
interaction may be an example of how cells cope with dislocated
proteins that escape degradation. Could it be that the machineries
for translocation and dislocation share certain co-factors?
Intriguingly, BAT3 has recently been implicated in proteasomal
degradation of newly synthesized defective polypeptides [62]. This
might suggest that cytosolic quality control machineries handle
defective, ribosome-derived nascent chains similarly to how they
deal with defective polypeptides that originate from the ER. The
specifically enriched association of the TRiC/CCT with RI332 in
UBX-EBV WT expressing cells (Figure 5) further supports this
interpretation: Cytosolic chaperone complexes implicated in the
stabilization and quality control of folding intermediates prior to
translocation in the ER [47,48] also interact with an ER-derived,
dislocated protein.
The approach developed here—expression of the EBV-DUB—
stabilizes a range of proteins that are normally degraded in an Ub-
dependent manner. Although capable of blocking Ub-dependent
protein degradation globally and efficiently, the EBV-DUB is less
toxic to cells than pharmacological proteasome inhibitors,
providing an extended window of observation. We show that
dislocation and degradation of ER-derived misfolded substrates
can be uncoupled by the expression of the viral DUB domain and
so allows the unprecedented visualization of a deglycosylated
dislocation intermediate in the absence of pharmacological
proteasome inhibitors. We identify the necessity of a DUB-
catalyzed reaction for protein dislocation from the ER and place
this activity upstream of p97. The determination of the sets of
interacting partners of a misfolded, ER-derived glycoprotein at
different stations on its road to destruction helped us characterize
the order of events during dislocation and degradation. The
expression of this highly active DUB has provided new
mechanistic insights into protein quality control. Given its low
toxicity and the possibility of achieving cell-type or tissue-specific
expression in vivo, the EBV-DUB and variants derived from it
may prove to be an attractive alternative to the use of small
molecule inhibitors of the proteasome.
Materials and Methods
Antibodies, Cell Lines, Constructs, Experimental
Procedures
Antibodies against the HA-epitope were purchased from Roche
(3F10); anti-Flag, anti-Ubiquitin antibodies were purchased from
Sigma-Aldrich; and Lys48-specific anti-Ubiquitin antibodies (anti-
K48-Ub, clone Apu2) were purchased form Millipore. Anti-p97
and anti-BAT3 antibodies were purchased from Fitzgerald
Industries and Abcam, respectively. Polyclonal anti-OS9 and
anti-SEL1L antibodies were described previously [45,63]. A.E.
Johnson (Texas A&M University, TX) provided a plasmid
encoding perfringolysin O. Polyclomal anti-PDI serum (rabbit)
was generated with bacterially expressed human PDI. 293T cells
were cultured and transfected as previously described [63]. The
deletion constructs and mutants of YOD1 have been described
elsewhere [11]. All p97-targetting constructs were cloned into the
pcDNA3.1(+) vector system (Invitrogen) with a Kozak sequence
(GCCACC) inserted directly upstream to the Start-Codon, and
encoded for a N-terminal Flag-tag (DYKDDDK) followed by the
UBX domain of YOD1 (aa1–131). For the UBX-GFP construct,
these aa1–131 of YOD1 were followed by a LEGS linker
sequence and the aa2–239 of enhanced GFP (EGFP). The UBX-
EBV-DUB fusion construct comprised the aa1–128 of YOD1, a
GGGS linker sequence and the DUB domain of the EBV large
tegument protein BPLF1 (aa1–270). The construct coding
catalytically impaired p97 (p97 QQ) was described earlier [11].
Site directed mutagenesis of the EBV-DUB was performed with
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the QuikChange II mutagenesis kit (Stratagene). The predicted
catalytic cysteine residue at position 61 of the original EBV
protein BPLF1 was mutated to alanine (C61A), threonine (C61T),
serine (C61S), or lysine (C61K). The isoleucine at position 173
and alanine at position 178 were mutated to tryptophane (I173W)
and to arginine (A178R), respectively. Maria Masucci provided
the Ub-R-GFP and the Ub-G76V-GFP construct. Untagged
RI332 was a generous gift from N. Erwin Ivessa. The Plasmid
pCMV-INSIG-1-Myc was obtained from the American Type
Culture Collection (ATCC number 88099). HA-RI332 was cloned
into pcDNA3.1(+) via HindIII and XbaI restriction sites. The HA-
epitope (YPYDVPDYA) and a GSLE linker sequence were
inserted between aa27 and aa28 of the signal sequence.
Pulse-Chase Experiments, Immunoprecipitations, Gel
Electrophoresis, Immunoblotting, and Transient
Transfections
Pulse chase experiments were performed as previously described
[38]. Prior to pulse labeling, the cells were starved for 30 min in
methionine/cysteine-free DMEM at 37uC. Cells were then labeled
for 10 min at 37uC with 250 mCi of [35S]methionine/cysteine
(PerkinElmer). De novo protein synthesis was quantitated in a
pulse labeling experiment. Where indicated, 50 mM ZL3VS was
applied to the cells during the starvation, pulse labeling, and chase
period. Incorporated radioactivity was quantified after SDS-
mediated cell lysis and TCA precipitation.
Transient transfection, cell lysis, immunoprecipitations and
transfections, SDS-PAGE, and fluorography were performed as
described earlier [34]. All quantifications were performed on a
phosphoimager.
For the protease protection assay cells were homogenized by
passing through a 23 x g needle in hypotonic buffer (20 mM
Hepes pH 7.5, 5 mM KCl, 5 mM MgCl2, 1 mM DTT, and a
protease protection cocktail (Roche)). Proteinase K was added to a
final concentration of 100 mg/ml in the presence and absence of
0.5% NP40. After 20 min on ice, the proteinase K was inactivated
by inclusion of PMSF (5 mM) and samples were analyzed by SDS-
PAGE.
Selective Plasmamembrane Permeabilization and
Subcellular Fractionation
For selective permeabilization of the plasmamembrane, cell 293T
cells were trypsinized harvested and washed with PBS. Perfringo-
lysin O was added to a final concentration of 0.5 mM at 0uC
followed by an incubation of the cells at 37uC for 15 min to induce
pore-formation. Where indicated, the mixture was adjusted to
0.5 M NaCl. Centrifugation (5 min, 9000 x g) separated cytosolic
proteins in the supernatant from cellular remnants in the pellet. The
pellet was washed with ice-cold PBS and lysed in PBS/1% SDS to
solubilize membrane proteins and release organelle contents.
Structural Modeling
Structural modeling is described in Text S1.
Data Analysis and Clustering
Data analysis and clustering are described in the Supporting
Information section.
Confocal Microscopy
Cells were grown on coverslips, fixed in 4% paraformaldehyde,
quenched with 20 mM glycerine, 50 mM NH4Cl, and permea-
bilized in 0.1% Triton X-100 at room temperature. Fixed and
permeabilized cells were blocked in 4% BSA and incubated either
with anti-HA antibodies (3F10, rat monoclonal, Roche) or anti-
PDI (Abcam) antibodies as described [45]. Images were acquired
by using a spinning disk confocal microscope, a Nikon 606
magnification, and a 16 numerical aperture oil lens.
Flow Cytometry
Cells were harvested by trypsinization 10 h after addition of
proteasome inhibitors and 20 h after transient transfection. Cells
were washed and incubated for 30 min at 4uC with a LIFE/
DEAD cell viability stain (Invitrogen). Subsequently, cells were
washed and fixed with 2% paraformaldehyde. Fluorescence
intensity of GFP was measured with LSR I flow cytometer (BD
Biosciences). Data were collected with CellQuest (BD Biosciences)
and analyzed with FlowJo (Tree Star).
Cell Morphology
Cells were transiently transfected with EBV-DUB WT or empty
vector. After 6 h, pharmacological proteasome inhibitors (10 mM
MG132 or 10 mM ZL3VS) were applied to the cells. Photographs
were taken 20 h post-treatment.
Supporting Information
Figure S1 EBV-DUB switches the cellular ubiquitylation
balance towards deubiquitylation. 293T cells were transfected as
indicated and immunoblotted with anti-Ub (left panel) and anti-
K48-Ub antibodies (right panel). An immunoblot with anti-BAT3
antibodies serves as loading control. Where indicated, cells were
treated for 1 h with 50 mM ZL3VS.
Found at: doi:10.1371/journal.pbio.1000605.s001 (0.69 MB TIF)
Figure S2 EBV-DUB blocks proteasomal degradation of Ub-
G76V-GFP and Ub-R-GFP. Flow-cytometric analysis of 293T
cells treated and co-transfected as indicated. The gate was set to
identify GFP-positive, live cells. The fraction of GFP-positive cells
is given for each panel. Quantified is the median fluorescence
intensity (MFI) of GFP-positive cells. Where indicated, the cells
were treated with ZL3VS for 10 h prior to formaldehyde-fixation.
Found at: doi:10.1371/journal.pbio.1000605.s002 (0.52 MB TIF)
Figure S3 EBV-DUB uncouples dislocation and degradation.
293T cells were co-transfected with RI332 and UBX-EBV WT and
subjected to a pulse chase experiment. After indicated time points,
RI332 was immunoprecipitated, subjected to SDS-PAGE, and
quantified. The fraction of deglycolated RI332 (RI332 -CHO) was
determined and plotted versus the chase time (right panel).
Found at: doi:10.1371/journal.pbio.1000605.s003 (0.27 MB TIF)
Figure S4 EBV-DUB can be targeted to p97 by N-terminal
attachment of an UBX domain. (A) 293T cells were transiently
transfected with the indicated constructs and homogenized in
NP40-containing lysis buffer 24 h after transfection. To control for
expression of YOD1 variants and chimeric fusions of the YOD1
UBX-domain to GFP and the EBV-DUB, the lysates were
subjected to immunoblotting with anti-FLAG antibodies. Anti-p97
antibodies were used to control for equal loading (two upper
panels). Retrieved p97 and Derlin-1 from anti-FLAG immuno-
precipitates was detected by immunoblotting with anti-p97 and
anti-Derlin-1 antibodies, respectively (lower panels). (B) 293T cells
were transiently transfected with the indicated constructs. Cell
lysates were prepared as in (A). Retrieved p97 and Derlin-1 in anti-
FLAG immunoprecipitates was detected by immunoblotting with
anti-p97 and anti-Derlin-1 antibodies, respectively (lower panels).
The numbers on the left of individual figures represent the
molecular weight standard in kDa.
Found at: doi:10.1371/journal.pbio.1000605.s004 (1.09 MB TIF)
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Figure S5 EBV-DUB and the p97-targeted UBX-EBV-DUB
block degradation of cytosolic substrates. Flow-cytometric analysis
of 293T cells treated and co-transfected as indicated. The gate was
set to identify GFP-positive, live cells. The fraction of GFP-positive
cells is given for each panel. Quantified is the median fluorescence
intensity (MFI) of GFP-positive cells.
Found at: doi:10.1371/journal.pbio.1000605.s005 (0.30 MB TIF)
Figure S6 Structural formulas of eeyarestatin-I and bromoben-
zene. The two halogenated benzene rings of eeyarestatin-I are
highlighted with red ellipses.
Found at: doi:10.1371/journal.pbio.1000605.s006 (0.12 MB
DOC)
Table S1 Interactome of RI332. List of proteins exhibiting
enriched interaction with RI332 when protein degradation and/or
dislocation were blocked by different means (listed in Figure 4).
The table gives the protein/gene names, Swiss-Prot accession
number, the number of peptides that could be identified under
optimal conditions in an LC/MS/MS experiment, the conditions
under which the MNOP was observed, and the resulting sequence
coverage.
Found at: doi:10.1371/journal.pbio.1000605.s007 (0.09 MB
DOC)
Text S1 Supporting materials and methods.
Found at: doi:10.1371/journal.pbio.1000605.s008 (0.06 MB
DOC)
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